Snapshot from Sep 02, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / ARS Pharmaceuticals Securities Fraud...
Regulatory securities class action

ARS Pharmaceuticals Securities Fraud Class Action

Analysis based on 7 articles · First reported Aug 28, 2026 · Last updated Sep 02, 2026

Sentiment
-30
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit could negatively impact ARS Pharmaceuticals' stock price and investor confidence, as it alleges securities fraud. The outcome may lead to financial penalties or settlements, affecting the company's balance sheet and reputation.

Pharmaceuticals Legal Services
Event Summary

Rosen Law Firm, a global investor rights law firm, has filed a class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) on behalf of purchasers of its securities between March 9, 2026 and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals and certain defendants made false and misleading statements and/or concealed material adverse facts regarding the expected timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Specifically, the defendants expressed confidence that coverage would begin on July 1, 2026, in time for the summer and back-to-school allergy seasons, but the true details later emerged, causing investors to suffer damages. The lead plaintiff deadline is October 5, 2026. Rosen Law Firm is reminding affected investors of this deadline and inviting them to join the class action.

Key Actions
90 Rosen Law Firm filed class action ARS Pharmaceuticals
Entities Involved
priv
ARS Pharmaceuticals
ARS Pharmaceuticals is the defendant in the securities fraud class action. The lawsuit alleges misleading statements about insurance coverage for its product neffy, which could lead to financial damages and reputational harm.
Importance 100.0 Sentiment -50.0
priv
Rosen Law Firm
Rosen Law Firm filed the class action lawsuit and is actively seeking lead plaintiffs. The firm stands to gain from a successful settlement or judgment.
Importance 80.0 Sentiment 20.0
stock
CVS Health
CVS Health is mentioned as the counterparty in the insurance coverage discussions for neffy. The lawsuit may implicate CVS Health's role, but no direct allegations are made against it.
Importance 40.0 Sentiment -10.0
per
Lawrence Rosen
Lawrence Rosen is a founding partner of Rosen Law Firm and is listed as a contact for the class action. His involvement is part of the firm's legal representation.
Importance 30.0 Sentiment 10.0
per
Philip Kim
Philip Kim is an attorney at Rosen Law Firm and is listed as a contact for the class action. His role is to assist investors in joining the lawsuit.
Importance 30.0 Sentiment 10.0
Relationships
Rosen Law Firm related ↔ Lawrence Rosen
Rosen Law Firm related ↔ Philip Kim
Lawrence Rosen managing partner ↔ Philip Kim Lawrence Rosen is the founder and managing partner of Rosen Law Firm, where Philip Kim is a partner, and they actively c
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.